Corcept Therapeutics Inc
CORT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001088856
In the last 90 days, Corcept Therapeutics Inc insiders filed 0 open-market purchases and 21 sales; 424 institutions reported holding it in 13F filings for Q2 2026, worth $7.15B in total; no superinvestor holds it.
Holders of 5% or more of CORT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Corcept Therapeutics Inc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ingalls & Snyder LLC | 13G/A | 7.80%8.17M shares | – | Feb 21, 20251 filing | Feb 21, 2025 | SEC |
| Belanoff Joseph K | 13G/A | 6.30%6.82M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Corcept Therapeutics Inc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Apr 23, 20257:09 AM ET | BlackRock, Inc. | 13G/A | 12.70%13.3M shares | – | Mar 31, 2025 | SEC |
| Feb 21, 20255:23 PM ET | Ingalls & Snyder LLC | 13G/A | 7.80%8.17M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20259:08 PM ET | Belanoff Joseph K | 13G/A | 6.30%6.82M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Corcept Therapeutics Inc shares.
No Form 144 notices for Corcept Therapeutics Inc are on file.